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Abstract The effects of 3-aminobenzamide (3ABm) and 
benzamide (BAm), known specific inhibitors of poly(ADP-
ribose) polymerase (PARP), on actinomycin D (Act D)-induced 
apoptosis in HL-60 cells were examined. These inhibitors had no 
appreciable effect on apoptotic DNA fragmentation, chromatin 
condensation or PARP restriction cleavage, but clearly inhibited 
morphological changes, especially nuclear fragmentation and 
apoptotic-body formation, in a dose-dependent manner. These 
results suggest that the synthesis of ADP-ribose polymers is not 
essential for the progression of apoptotic DNA fragmentation 
and chromatin condensation, but is required in the processes 
leading to nuclear fragmentation and the subsequent apoptotic-
body formation during apoptosis in HL-60 cells. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Apoptosis is gene-directed active cell death caused by a 
variety of physiological and pathological stimuli [1-4]. Cell 
death by apoptosis is characterized by specific morphological 
patterns including the disappearance of microvilli, cell shrink-
age, chromatin condensation, nuclear collapse and cellular 
fragmentation into apoptotic-bodies [5-7]. In most cases, 
these morphological changes are accompanied by internucleo-
somal D N A fragmentation [7-10]. Although many molecules 
participating in apoptosis have recently been reported, the 
molecular mechanisms by which these morphological changes 
are regulated remain unknown. 
The poly(ADP-ribosyl)ation of chromosomal proteins is a 
post-translational modification that occurs in eukaryotic cells 
[11-13]; its physiological roles are suggested to include the 
regulation of D N A replication, repair and transcription 
through modulat ion of the chromatin structure [14-17]. Re-
cently, a poly(ADP-ribose) synthetic enzyme, PARP, has been 
shown to be activated during the early stage of apoptosis in 
many cell types [18-24]. Fur thermore, P A R P is proteolytically 
digested to 85 and 30 k D a fragments by caspase family during 
apoptosis [24-26]. Thus, the importance of poly(ADP-ribo-
syl)ation in apoptosis has recently become a focus of research. 
However, the role of poly(ADP-ribosyl)ation during apoptosis 
remains unclear. 
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To address the significance of poly(ADP-ribosyl)ation in 
apoptosis, we examined the effects of P A R P inhibitors on 
apoptosis in HL-60 cells. The results show that specific inhib-
itors of P A R P suppress nuclear fragmentation and apoptotic-
body formation without affecting chromatin condensation or 
D N A fragmentation. Our findings suggest that poly(ADP-ri-
bosyl)ation plays an important role in late stage morpholog-
ical changes that occur during apoptosis in HL-60 cells. 
2. Materials and methods 
2.1. Materials 
3-Aminobenzamide (3ABm), benzamide (BAm), 3-amonobenzoic 
acid (3BAc), benzoic acid (BAc), actinomycin D (Act D), BSA frac-
tion V, RNase A and Proteinase K were purchased from Sigma. 
Glutaraldehyde was from Seikagaku Kougyou. Hoechst 33258 was 
from Hoechst Japan. Immobilon PSQ was from Millipore. All other 
reagents were of analytical grade. The polyclonal antibody against 
human PARP was a gift of Dr. Miwa M. and Dr. Uchida K. (Uni-
versity of Tsukuba, Japan). 
2.2. Cell culture and induction of apoptosis 
The human promyelocytic leukemia cell line HL-60 was maintained 
in suspension culture in RPMI-1640 medium supplemented with 10% 
heat-inactivated fetal calf serum (Bocknek Ltd.). HL-60 cells were 
precultured for 1 h in the presence or absence of various concentra-
tions of 3ABm or BAm. Apoptosis was induced by the addition of 
1 ug/ml Act D to the culture medium. 
2.3. Assay of DNA fragmentation 
1 X 106 Cells were collected by centrifugation at 400 Xg and lysed in 
lysis buffer (50 mM Tris-HCl (pH 7.8), 10 mM EDTA, 0.5% (w/v) 
sodium JV-lauroyl sarcosinate). The DNA was prepared by successive 
treatments with 0.5 mg/ml RNase A for 20 min and 0.5 mg/ml pro-
teinase K for 30 min at 50°C. The resulting DNA preparation was 
subjected to electrophoresis in 2% agarose gels. DNA fragmentation, 
visualized by ethidium bromide staining, was examined in photo-
graphs taken under UV-illumination [32]. 
2.4. Western blot analysis 
Total proteins from 2X 10° cells were separated by SDS-PAGE and 
transferred onto PVDF membrane. Blots were blocked in TBST 
(20 mM Tris-HCl (pH 8.0), 400 mM NaCl, 0.05% (w/v) Triton 
XI00) containing 2.5% BSA for 1 h and probed with the anti-
PARP antibody. After washing with TBST, antibody retained on 
the membrane was detected using peroxidase-conjugated anti-guinea 
pig IgG (Jackson Immuno Research) and Proto Blot Western detec-
tion kit (Promega). 
2.5. Microscopic analyses 
Cells were collected by centrifugation at 400Xg and fixed with 1% 
glutaraldehyde in PBS(—) at room temperature for 10 min. After 
washing with PBS(—), the cells were stained with 1 mM Hoechst 
33258 in PBS(—) and observed under fluorescence microscopy. Trans-
mission electron microscopic analysis was performed as described pre-
viously [27,28]. The frequency of apoptotic cells was determined by 
counting the blebbing cells under phase-contrast microscopy. 
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Fig. 1. Phase-contrast microscopic analysis of the morphology of HL-60 cells treated with Act D for 6 h in the presence or absence of 3ABm 
or BAm. Control (a), 1 mM 3ABm (b), 1 mM BAm (c), 1 iig/ml Act D (d), 1 mM 3ABm and 1 iig/ml Act D (e), 1 mM BAm and 1 |xg/ml 
Act D (f). Magnification: X400. 
3. Results 
Treatment with Act D (1 |j.g/ml) caused typical apoptotic 
morphological changes in HL-60 cells. Shrunken cells began 
to appear after 3 h. By 6 h, about 90% of cells had turned into 
membrane-bound small particles, so-called apoptotic-bodies 
(Fig. ldFig. 4c,g). As illustrated in Fig. 4c,g, the character-
istics of apoptosis, such as chromatin condensation, nuclear 
fragmentation and the disappearance of cell surface microvilli, 
were clearly observed. We next examined whether these mor-
phological changes were followed by nuclear DNA fragmen-
tation and PARP cleavage. As shown in Fig. 2d,g (upper 
panel), internucleosomal DNA cleavage and proteolysis of 
PARP occurred in a time-dependent manner. These results 
show that Act D induces typical apoptosis in HL-60 cells. 
To address the importance of poly(ADP-ribosyl)ation in 
apoptosis, we examined the effects of the PARP inhibitors 
3ABm and BAm on apoptosis in HL-60 cells. Neither 
3ABm nor BAm (1 mM) alone had any essential cytotoxic 
effect on HL-60 cells. Neither morphological abnormalities 
(Fig. lb,cFig. 4b,f) nor DNA fragmentation (Fig. 2b,c) was 
observed and cell viability also remained at control levels 
(data not shown). Next, we induced apoptosis in the presence 
of PARP inhibitors. HL-60 cells were pretreated with 3ABm 
or BAm (1 mM) for 1 h and apoptosis was induced by the 
addition of Act D (1 ug/ml). Microscopic analysis revealed 
that the cell shrinkage and apoptotic-body formation, which 
were observed in apoptosis caused by Act D alone, were 
strongly inhibited by 3ABm or BAm (Fig. le,f). As shown 
in Fig. 3a, the suppression of apoptotic-body formation by 
PARP inhibitors was achieved in a dose-dependent manner. 
Half-maximal inhibition by BAm and 3ABm was obtained at 
140 uM and 200 uM, respectively (Fig. 3a). In contrast, 3ABc 
and BAc, non-inhibitory analogues of 3ABm and BAm, re-
spectively, had no effects on apoptotic-body formation (Fig. 
3a), suggesting that morphological suppression by PARP in-
hibitors is not due to non-specific effects but to the inhibition 
of PARP. 
In contrast, apoptotic DNA fragmentation occurred nor-
mally in the presence of 3ABm or BAm (ImM) (Fig. 2e,f). 
The extent of DNA laddering was the same as that induced by 
Act D alone (Fig. 2d). Western blot analysis using the anti-
PARP polyclonal antibody revealed that proteolytic cleavage 
of PARP was not also affected by 1 mM 3ABm (Fig. 2g, 
lower panel). The presence of up to 10 mM 3ABm had no 
effect on DNA fragmentation (Fig. 3b, upper panel). 
Although a slight inhibition was observed at higher BAm 
concentrations (Fig. 3b, lower panel), this was thought to be 
an artificial effect of BAm, because the concentration required 
for the inhibition of DNA fragmentation was significantly 
higher than that required for PARP inhibition [29]. 
To examine morphological suppression by PARP inhibitors 
in greater detail, we further examined the cells by fluorescence 
and electron microscopies. Fig. 4 clearly shows the suppres-
sion of nuclear fragmentation and apoptotic-body formation 
by 3ABm. However, PARP inhibitors could not prevent other 
apoptotic morphological changes. Fig. 4d,h show the failure 
of 3ABm to suppress chromatin condensation around the nu-
clear envelope or the disappearance of microvilli during apop-
tosis in HL-60 cells. The same results were obtained with 
BAm, but not 3ABc or BAc (data not shown). 
4. Discussion 
Since inhibitors of RNA or protein synthesis can prevent or 
delay the induction of apoptosis, the processes are thought to 
be under the regulation of suicide-genes and to require the 
new synthesis of proteins encoded by these genes [30-32]. 
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Fig. 2. Analyses of DNA and PARP cleavages in HL-60 cells treated with Act D in the presence or absence of PARP inhibitors. Apoptosis 
was induced by 1 ug/ml Act D in the absence or presence of 1 mM 3ABm. HL-60 cells were harvested at the indicated times after the induc-
tion of apoptosis and subjected to agarose gel electrophoresis (a-f) and Western blot analyses (g) as described in Section 2. Control (a), 1 mM 
3ABm (b), 1 mM BAm (c), 1 ug/ml Act D (d,g, upper panel), 1 mM 3ABm and 1 ug/ml Act D (e,g, lower panel), 1 mM BAm and 1 ug/ml 
Act D (f). The 116 and 85 kDa bands represent intact and cleaved PARP, respectively. 
However, these inhibitors are also known to induce or en-
hance apoptosis in some cell types [33-35]. In this study, we 
show that an RNA synthesis inhibitor, Act D, by itself indu-
ces typical apoptosis in HL-60 cells. This is consistent with 
previous reports [18,33,34] and suggests the existence of a new 
gene-expression-independent pathway(s) for apoptosis in this 
system. 
By using this system, we examined the role of poly(ADP-
ribosyl)ation in the process(es) of apoptosis. Our data of agar-
ose gel electrophoresis clearly showed PARP inhibitors 3ABm 
or BAm to have no appreciable effect on apoptotic DNA 
fragmentation. The progression of DNA fragmentation oc-
curred normally regardless of the presence of the PARP in-
hibitors. Furthermore, we saw no changes in the DNA ladder 
patterns in the presence of 3ABm up to 10 mM. These results 
suggest that the activation of PARP, poly(ADP-ribose) for-
mation, is not essential in the cleavage of genomic DNA to 
nucleosomal units. 
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Fig. 3. Dose effects of PARP inhibitors on apoptotic-body formation (a) and DNA fragmentation (b) during Act D-induced apoptosis of HL-
60 cells, (a) Apoptosis was induced by 1 ug/ml Act D in the presence of increasing concentrations of 3ABm (-•-), BAm (-■-), 3-ABc (-o) or 
BAc (-□-). Apoptotic cells (apoptotic-body formation) were counted under phase-contrast microscopy after 6 h of treatment. Values are the 
averages of three separate experiments, (b) DNA fragmentation in the presence of 3ABm (upper panels) or BAm (lower panels) at concentra-
tions of 0, 0.01, 0.03, 0.1, 0.3, 1, 3 or 10 mM (lanes 1-8, respectively) was analyzed by 2% agarose gel electrophoresis. 
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Fig. 4. Fluorescence (a-d) and transmission electron (e-h) microscopic analyses of HL-60 cells treated with Act D for 6 h in the presence or 
absence of 3ABm. Control (a,e), 1 mM 3ABm (b,f), 1 iig/ml Act D (c,g), 1 mM 3ABm and 1 lig/ml Act D (d,h). Magnifications: XlOOO (fluo-
rescence microscopy); X2500 (transmission electron microscopy). 
In contrast, microscopic analyses revealed that some apop-
totic morphological changes in HL-60 cells were prevented by 
PARP inhibitors. Importantly, nuclear fragmentation and 
subsequent apoptotic-body formation were strongly sup-
pressed, although the disappearance of microvilli and chroma-
tin condensation were not inhibited by PARP inhibitors. 
These results suggest that poly(ADP-ribosyl)ation of specific 
acceptor proteins and/or poly(ADP-ribose) metabolism 
through synthesis by PARP and hydrolysis by poly(ADP-ri-
bose) glycohydrolase (PARG) [36-38] are required for nuclear 
collapse and apoptotic-body formation during the progression 
of apoptotic morphological changes (Fig. 5). The same results 
were obtained using camptothecin, adriamycin or cychrohex-
imide as apoptosis inducers, indicating that the morphological 
suppression is not restricted to Act D-induced apoptosis. 
The involvement of poly(ADP-ribosyl)ation in the apop-
totic morphological changes seems to be contradictory to 
the proteolysis of PARP during apoptosis. The restriction 
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Fig. 5. Schematic illustration of the progression of apoptotic morphological changes in the presence or absence of PARP inhibitors. 
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cleavage of P A R P is actually observed in our experimental 
system regardless of the existence of 3ABm. Previous studies 
have shown that P A R P activation after induction of apoptosis 
precedes the commitment of cell death [18-24], and that pro-
teolysis of PARP by caspase family occurs after the cells pass 
on the point of no-return [24-26]. Fig. 2g shows that P A R P 
remains intact until 2 h after induction of apoptosis and be-
gins to be proteolyzed as death by apoptosis goes on. There-
fore, the morphological suppression by P A R P inhibitors is 
thought to be due to the inhibition of P A R P activation during 
the initial phase of apoptosis. Tha t is, transient activation of 
P A R P is considered to be required for the morphological 
changes occurred in the latter stage. This explanation is sup-
ported by the observation that P A R P inhibitors could no 
longer suppress the morphological changes when they were 
added after the onset of P A R P cleavage (data not shown). 
The effects of P A R P inhibitors, including 3ABm and BAm, 
on apoptosis have previously been examined [21-23,39^13]. In 
these papers, P A R P inhibitors have shown to work inhibitory 
[21-23,39^-1] or stimulatory [41^43] on apoptosis and it de-
pends on cell types, culture conditions and apoptosis inducers. 
These facts indicate the involvement of poly(ADP-ribosyl)-
ation in multiple points of the pathways leading to and ex-
ecuting apoptosis. 
In this report, we show that P A R P inhibitors suppress nu-
clear fragmentation and apoptotic-body formation without 
affecting D N A fragmentation during the apoptosis of HL-60 
cells. At present, the reason why the inhibition of poly(ADP-
ribosyl)ation results in this suppression is unknown. Elucida-
tion of the molecular mechanism(s) by which poly(ADP-ribo-
syl)ation is involved in the morphological changes of apopto-
sis is the next target of study. 
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